IKAROS is a chromatin-remodeling and sequence-specific transcription factor encoded by the IKZF1 gene that is involved in a number of developmental processes in hematopoiesis. In particular, IKAROS is essential for the specification of the lymphoid lineages from myeloid/lymphoid multipotent progenitors, is involved in the differentiation of pro-B cells into pre-B cells and, together with the related IKAROS family member Aiolos, downregulates pre-BCR function (for a review, see Nutt and Kee 1 ). Over the past 10 years, reverse transcription-PCR studies have reported the expression of short IKAROS isoforms in acute lymphoblastic leukemia (ALL) patients at diagnosis, with higher prevalence in BCR-ABL-associated B-ALL. 2 These short isoforms encode IKAROS proteins that include only two out of the four central zinc fingers responsible for their specific binding to DNA while keeping intact the C-terminal zinc fingers involved in their oligomerization with DNA-binding-competent isoforms of IKAROS and other IKAROS family members. Thus, these short isoforms can function as dominant-negative (DN) mutants of wild-type (wt) IKAROS and IKAROS family members. Recently, comprehensive genome-wide SNP array analyses of DNA copy number alterations in ALL showed the frequent monoallelic deletion of all or part of IKZF1, the latter situation often linked to the expression of DN IKAROS isoforms in 475% of pediatric and 490% of adult BCR-ABL B-ALL and lymphoid blast crisis chronic myeloid leukemia (CML) patients. 3 These data suggest that impaired function of IKAROS itself, and possibly of other members of the IKAROS family, could be instrumental in BCR-ABL-induced B-ALL progression and poor clinical outcome. 4 To investigate whether impaired IKAROS function can facilitate BCR-ABL-induced leukemogenesis, we crossed BCR-ABL transgenic mice that exclusively develop B-ALL 5 with mice carrying an hypomorphic IKZF1 allele (IK L ). 6 Previous studies have shown that the IK L allele, generated by the knock-in of Lac Z into IKZF1 exon 2, produces 5-10% of wt levels of IKAROS proteins that lack amino acids encoded by exon 2. Importantly, these mutant proteins were as efficient as wt IKAROS at rescuing abnormal phenotypes from homozygous mutant mice, suggesting that the IK L allele is mainly, if not exclusively, a loss of function allele. 7, 8 Two cohorts of BCR-ABL þ compound mice were generated that carried either two alleles of wt IKZF1 (BCR-ABL Figure 1a) . Strikingly, leukemia onset was considerably accelerated in BCR-ABL þ /0 ; IK L/ þ mice (median latency of 5.7 weeks; Figure 1a) . None of the control groups developed disease during a 6-month observation period (Figure 1a ; data not shown). Histologically, the leukemias arising from both the BCR-ABL
; IK L/ þ cohorts were similar, with recurrent leukemic cell infiltration of bone marrow, spleen, lymph nodes, blood and nonhematopoietic tissues including liver and brain (data not shown). Flow cytometry analyses identified large leukemic blasts in both cohorts that were B220
þ sIgM À with a variable proportion of CD43 þ cells in individual leukemias (Figures 1b and c leukemic cells showed the expected 50% decrease in expression in IK1/2 and the expression at low levels of the N-terminally shortened IK1/2 n polypeptides encoded by the hypomorphic IKAROS allele, 6 but no expression of DN IKAROS isoforms. This indicates that the experimentally imposed impaired function of IKZF1 does not favor the inactivation of the remaining wt allele during leukemia progression. Hemizygous deletion of PAX5 is observed in about 50% of BCR-ABL-positive B-ALL patients. 3 Western blot analysis failed to detect any change in Pax5 expression in leukemic cells obtained from our BCR-ABL transgenic cohorts irrespective of their IKAROS status, as compared with normal B-cell progenitors (Figure 1d ). We conclude from these experiments that loss of a single wt IKZF1 allele is sufficient to cooperate strongly with BCR-ABL in B-cell leukemogenesis. PCR analysis of the V H -to-DJ H immunoglobulin heavy chain (IgH) locus rearrangement using 5 0 primers specific for distal (V H J558) or proximal (V H Gam3. 
Mice harboring a BCR-ABL construct encoding P190 BCR-ABL under control of the metallothionein promoter 5 were obtained from the Jackson Laboratory (Charles River Laboratories, L'Arbresle, France), re-derived and backcrossed for eight generations on C57B/6 mice. These mice were crossed to IK L/ þ mice, 6 maintained on C57B/6 background and the resulting cohorts of BCR-ABL
Cohorts of control IK L/ þ (n ¼ 10; hatched line) and nontransgenic littermates (not shown) were also analyzed. Mice were killed when moribund (mobility weakness or paralysis, lusterless fur, respiratory distress). Survival curves were plotted using the Prism 4 software (Graph Pad Software Inc., San Diego, CA, USA). The P-value (o0.0001 ; IK þ / þ leukemias indicate that impaired IKAROS function facilitates leukemia progression and accelerates tumor onset by bypassing the requirement to select for and accumulate specific additional pro-oncogenic genetic hits that cooperate with BCR-ABL in B-cell leukemogenesis.
Therapies targeting the tyrosine kinase domain of BCR-ABL, for example, imatinib, are the first-line treatment of CML patients and show remarkable success in the chronic phase of the disease. These treatments do not induce lasting remission for patients in blast crisis and for patients with BCR-ABL-associated B-ALL. Imatinib administered in combination with chemotherapy during the induction or consolidation phase is associated with improved clinical responses, but relapse and drug resistance are common (for review, see Gruber et al. 9 ). Drugs targeting either signaling molecules downstream of BCR-ABL, or molecular pathways that synergize with BCR-ABL in leukemia maintenance, will likely offer additional therapeutic options. The mouse model described here will be an important tool to identify and dissect the role 
cells and CD4
þ CD8 þ thymocytes were used as positive and negative controls, respectively. The primers used and PCR conditions were as described previously.
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WT1 gene, originally identified as a tumor suppressor involved in the formation of Wilms' tumor of the kidney, was subsequently described to have an oncogenic role in a variety of tumors from different origins, including leukemias. 1 In comparison to normal progenitor cells, it is overexpressed in acute lymphoblastic and myeloblastic leukemia, and in the blast crisis phase of chronic myelogenous leukemia; 1,2 high levels of the protein are associated with a poor response to therapy.
1,3 WT1 knockdown by antisense oligonucleotides or RNA interference was shown to induce apoptosis; conversely, its overexpression in myeloid leukemia cells protected against cell death. Modulation of some members of the bcl-2 family has been associated with apoptosis inhibition by WT1. 1, 3 Among proteins that regulate apoptosis in leukemia cells, a role is assigned to BAG3, a member of the family of proteins that, through their BAG domain, interact with HSC70/HSP70 heat shock proteins. bag3 gene expression is constitutive in some tumor types, including leukemias; in these cells, BAG3 protein has been shown to sustain cell survival and downmodulate cell apoptotic response to drugs, by either HSP70-dependent or -independent mechanisms. [4] [5] [6] [7] Here we report that WT1 induces bag3 gene expression. This finding identifies a novel target of WT1 protein involved in apoptosis regulation in leukemia cells.
As using in silico analysis we had found two putative WT1 binding sites on the bag3 promoter, we decided to investigate whether WT1 is directly recruited onto the bag3 promoter using a chromatin immunoprecipitation assay (ChIP) in K562 cells, which express significant amounts of endogenous WT1 and BAG3. Chromatin was immunoprecipitated with anti-WT1 antibodies. Subsequent PCR analysis, performed using oligonucleotides covering the putative WT1 binding sites, revealed that WT1 bound to the bag promoter sequences (350-bp band), whereas rabbit IgG antibody controls did not (Figure 1a) . WT1 protein has two major isoforms, designated WT1(-KTS) and WT1(+KTS), containing an extra three aminoacids (KTS) between the third and fourth zinc fingers; WT1(ÀKTS) appears to exert its effect mainly as a transcriptional factor, whereas WT1( þ KTS) is involved in RNA processing. 1 To investigate the transcriptional modulation of bag3 promoter by WT1, we introduced a luciferase reporter plasmid containing the bag3 promoter into HEK293 cells and analyzed luciferase levels in the presence of increasing amounts of WT1(ÀKTS) or WT1( þ KTS) expression plasmids. As shown in Figure 1b , the 'transcriptional isoform', WT1(ÀKTS), enhanced bag3 promoter activity in a dose-dependent manner, whereas transfection of the 'posttranscriptional isoform', WT1( þ KTS), did not influence the transcriptional activity.
To assess whether forced expression of WT1 isoforms could modulate endogenous bag3, we transfected HEK293 cells with increasing concentrations of the expression vectors encoding WT1(ÀKTS) or WT1( þ KTS) and evaluated bag3 mRNA and BAG3 protein levels by quantitative real-time-PCR and western blot analyses, respectively. We observed a progressive increase in the levels of bag3 RNA and BAG3 protein in cells transfected with increasing amount of WT1(ÀKTS), and not in those transfected with WT1( þ KTS) (Figures 1c-d) , confirming the transcriptional activation of endogenous bag3 gene by WT1.
To provide a further argument for bag3 regulation by WT1, we evaluated bag3 expression in K562 cells following small interfering RNA (RNAi)-mediated knockdown of WT1. As shown in Figure 1e , the levels of bag3 mRNA in WT1 knockdown cells were decreased by about 40%; western blotting confirmed downmodulation of BAG3 protein.
Altogether, these observations ascribe a role to WT1 in bag3 gene regulation.
We next evaluated the effect of WT1 silencing on apoptosis. In K562 cells treated with the proapoptotic agent phenethyl isothiocyanate (PEITC), WT1 silencing significantly enhanced apoptosis, as assessed by flow cytometry, with respect to control scrambled RNA (Figure 2a) . Conversely, BAG3 protein appeared to exert an antiapoptotic effect against PEITC treatment, since its overexpression obtained by cell transduction with a bag3 cDNA-carrying adenovirus (AdhBAG3) downmodulated PEITC-induced apoptosis (Figure 2b) . We therefore investigated
